A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers
Part of paid clinical trials in Lincoln, Nebraska.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT01463774
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Treatment A: Canagliflozin tablet — DRUGType=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
- Treatment A: Metformin IR tablets — DRUGType=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
- Treatment B: Canagliflozin/metformin fixed dose combination tablets — DRUGType=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
Study Details
The purpose of this study is to evaluate the bioequivalence of a fixed dose combination tablet of canagliflozin and metformin immediate release (IR) in comparison with the individual components of canagliflozin and metformin IR.
Key Dates
- Start date
- Sep 30, 2011
- Status verified
- Nov 2012
- Primary completion
- Dec 31, 2011
- Completion
- Dec 31, 2011
Study Design
- Enrollment
- 74 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Sequence ABThe study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
- Experimental: Treatment Sequence BAThe study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
Primary Outcome Measure
Canagliflozin plasma concentrations [ Time Frame: Up to 72 hours ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Lincoln | Nebraska | - | - |
Related Studies
- A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).PHASE1 · Recruiting · Merck Sharp & Dohme LLC · Glendale, California
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their BabiesPHASE3 · Recruiting · Pfizer · Birmingham, Alabama
- A Phase 1 Study of BLKR201 in Healthy Adult ParticipantsPHASE1 · Recruiting · Formation Bio, Inc. · Lincoln, Nebraska
- Study of New Magnetic Resonance Imaging Methods of the BrainRecruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland